Published in Future Virol on January 01, 2010
Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci U S A (2014) 2.23
Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem (2012) 1.85
New generation humanized mice for virus research: comparative aspects and future prospects. Virology (2013) 1.38
HIV latency in the humanized BLT mouse. J Virol (2011) 1.19
HIV/AIDS eradication. Bioorg Med Chem Lett (2013) 0.98
Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug delivery. ACS Nano (2014) 0.84
Targeting IκB proteins for HIV latency activation: the role of individual IκB and NF-κB proteins. J Virol (2013) 0.84
Studies of retroviral infection in humanized mice. Virology (2015) 0.83
Stelleralides D-J and Anti-HIV Daphnane Diterpenes from Stellera chamaejasme. J Nat Prod (2015) 0.75
Experimental Approaches for Eliminating Latent HIV. For Immunopathol Dis Therap (2015) 0.75
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 28.54
Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet (2003) 25.57
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature (1987) 19.23
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 17.60
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
Decay characteristics of HIV-1-infected compartments during combination therapy. Nature (1997) 13.68
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
HIV-1 integration in the human genome favors active genes and local hotspots. Cell (2002) 12.60
High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science (1993) 12.22
Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J (2003) 11.27
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science (1988) 9.05
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med (2009) 8.45
The accuracy of reverse transcriptase from HIV-1. Science (1988) 8.24
Duration of antiviral immunity after smallpox vaccination. Nat Med (2003) 7.39
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science (1987) 7.22
Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science (1991) 7.15
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2008) 6.70
Identification of a putative regulator of early T cell activation genes. Science (1988) 6.62
Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A (1989) 6.32
In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med (1995) 6.26
Age-related changes in lymphocyte development and function. Nat Immunol (2004) 6.16
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J (2003) 6.11
Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A (2002) 6.09
Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med (2007) 6.01
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol (1992) 5.78
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell (2005) 5.71
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science (1997) 5.55
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
Retracted Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature (2005) 5.28
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA (1999) 4.98
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med (2005) 4.83
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog (2007) 4.82
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell (1990) 4.78
Infection of the SCID-hu mouse by HIV-1. Science (1988) 4.37
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J (2005) 4.35
Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J Exp Med (1999) 4.32
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med (2000) 4.12
Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J (1993) 3.95
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis (2005) 3.93
HIV induces thymus depletion in vivo. Nature (1993) 3.73
DNA methylation and gene expression: endogenous retroviral genome becomes infectious after molecular cloning. Proc Natl Acad Sci U S A (1981) 3.70
Long-term human hematopoiesis in the SCID-hu mouse. J Exp Med (1990) 3.59
Re-emergence of HIV after stopping therapy. Nature (1999) 3.54
The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol (2000) 3.43
The SCID-hu mouse as a model for HIV-1 infection. Nature (1993) 3.43
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS (2004) 3.17
Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol (2004) 3.17
Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol (1998) 3.09
Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood (2008) 3.05
Generation of HIV latency during thymopoiesis. Nat Med (2001) 2.91
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood (2001) 2.88
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. JAMA (1986) 2.86
Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe (2008) 2.81
Molecular characterization, reactivation, and depletion of latent HIV. Immunity (2003) 2.80
Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol (2003) 2.78
Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J (2007) 2.74
The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity (1997) 2.66
The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature (2003) 2.63
Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol (2002) 2.63
Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol (2005) 2.55
CpG methylation controls reactivation of HIV from latency. PLoS Pathog (2009) 2.51
Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog (2009) 2.50
Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem (2004) 2.47
Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS (2002) 2.40
Immunotoxin treatment of cancer. Annu Rev Med (2007) 2.36
Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci U S A (2007) 2.30
c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol (2007) 2.24
Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV. Science (2008) 2.23
Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J Virol (1998) 2.23
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med (2009) 2.21
CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J (2007) 2.20
Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc Natl Acad Sci U S A (1994) 2.14
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS (1999) 2.09
Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med (2004) 2.08
Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog (2006) 2.08
A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. Proc Natl Acad Sci U S A (1996) 2.06
Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes. J Virol (1999) 1.97
Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol (2002) 1.93
Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis (2002) 1.91
DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1. J Virol (1991) 1.90
A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem (1992) 1.80
In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol (2005) 1.80
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses (2004) 3.75
PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci U S A (2005) 2.93
Molecular characterization, reactivation, and depletion of latent HIV. Immunity (2003) 2.80
Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol (2002) 2.63
Female human iPSCs retain an inactive X chromosome. Cell Stem Cell (2010) 2.59
A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood (2009) 2.25
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med (2009) 2.21
Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci U S A (2002) 2.14
Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity (2012) 2.13
Expression-based monitoring of transcription factor activity: the TELiS database. Bioinformatics (2004) 2.03
Controlling false-negative errors in microarray differential expression analysis: a PRIM approach. Bioinformatics (2003) 2.02
Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol (2002) 1.93
Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem (2012) 1.85
T lineage differentiation from human embryonic stem cells. Proc Natl Acad Sci U S A (2006) 1.64
Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci U S A (2011) 1.61
Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc Natl Acad Sci U S A (2003) 1.58
HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. Blood (2013) 1.51
Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells. J Virol (2007) 1.45
Psychological risk factors for HIV pathogenesis: mediation by the autonomic nervous system. Biol Psychiatry (2003) 1.38
Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther (2004) 1.37
Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. J Infect Dis (2002) 1.33
Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection. J Interferon Cytokine Res (2005) 1.32
A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors. Genes Dev (2008) 1.27
Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proc Natl Acad Sci U S A (2013) 1.24
HIV latency in the humanized BLT mouse. J Virol (2011) 1.19
Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques. J Immunol (2007) 1.18
Impacts of epitope expression kinetics and class I downregulation on the antiviral activity of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. J Virol (2004) 1.17
Stress-induced enhancement of NF-kappaB DNA-binding in the peripheral blood leukocyte pool: effects of lymphocyte redistribution. Brain Behav Immun (2004) 1.17
CD4 on CD8(+) T cells directly enhances effector function and is a target for HIV infection. Proc Natl Acad Sci U S A (2004) 1.16
In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog (2012) 1.14
Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status. Stem Cell Res Ther (2013) 1.14
Activation of latent HIV using drug-loaded nanoparticles. PLoS One (2011) 1.10
Primary cell model for activation-inducible human immunodeficiency virus. J Virol (2007) 1.10
Human immunodeficiency virus integration efficiency and site selection in quiescent CD4+ T cells. J Virol (2009) 1.09
CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes. PLoS One (2010) 1.09
beta-Adrenoreceptors reactivate Kaposi's sarcoma-associated herpesvirus lytic replication via PKA-dependent control of viral RTA. J Virol (2005) 1.08
Eradication of HIV: current challenges and new directions. J Antimicrob Chemother (2008) 1.08
Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice. PLoS One (2009) 1.08
Activation of CD8 T cells induces expression of CD4, which functions as a chemotactic receptor. Blood (2002) 1.08
From skin biopsy to neurons through a pluripotent intermediate under Good Manufacturing Practice protocols. Stem Cells Transl Med (2011) 1.07
Rapid expression of human immunodeficiency virus following activation of latently infected cells. J Virol (2006) 1.04
Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus. Antivir Ther (2005) 1.02
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res (2014) 1.01
A self-renewal program controls the expansion of genetically unstable cancer stem cells in pluripotent stem cell-derived tumors. Stem Cells (2009) 0.98
HIV/AIDS eradication. Bioorg Med Chem Lett (2013) 0.98
The CD4 molecule on CD8+ T lymphocytes directly enhances the immune response to viral and cellular antigens. Proc Natl Acad Sci U S A (2005) 0.98
Human immunodeficiency virus bearing a disrupted central DNA flap is pathogenic in vivo. J Virol (2007) 0.98
Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression. Mol Ther (2013) 0.97
Genome-wide binding map of the HIV-1 Tat protein to the human genome. PLoS One (2011) 0.95
Effect of latent human immunodeficiency virus infection on cell surface phenotype. J Virol (2002) 0.94
Human immunodeficiency virus type 1 infection and replication in normal human oral keratinocytes. J Virol (2003) 0.94
Generation of T lineage cells from human embryonic stem cells in a feeder free system. Stem Cells (2009) 0.93
Cocaine exposure enhances permissiveness of quiescent T cells to HIV infection. J Leukoc Biol (2013) 0.93
CD4+ NK cells can be productively infected with HIV, leading to downregulation of CD4 expression and changes in function. Virology (2009) 0.93
Differentially stimulated CD4+ T cells display altered human immunodeficiency virus infection kinetics: implications for the efficacy of antiviral agents. J Virol (2009) 0.90
HIV-1 infection in peripheral blood lymphocytes (PBLs) exposed to alcohol. Virology (2003) 0.90
CD4 expression on activated NK cells: ligation of CD4 induces cytokine expression and cell migration. J Immunol (2006) 0.87
Short communication: Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages. AIDS Res Hum Retroviruses (2008) 0.87
Quiescent T cells and HIV: an unresolved relationship. Immunol Res (2010) 0.87
Alcohol enhances HIV type 1 infection in normal human oral keratinocytes by up-regulating cell-surface CXCR4 coreceptor. AIDS Res Hum Retroviruses (2004) 0.85
HIV type 1 infection alters cytokine mRNA expression in thymus. AIDS Res Hum Retroviruses (2003) 0.84
Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug delivery. ACS Nano (2014) 0.84
Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging. J Clin Invest (2015) 0.83
Differential expression and interaction of host factors augment HIV-1 gene expression in neonatal mononuclear cells. Virology (2010) 0.83
Macrophage differentiation from embryoid bodies derived from human embryonic stem cells. J Stem Cells (2009) 0.82
Phase I/II Clinical Trials Using Gene-Modified Adult Hematopoietic Stem Cells for HIV: Lessons Learnt. Stem Cells Int (2011) 0.82
Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages. Antimicrob Agents Chemother (2011) 0.80
Stem cell-based approaches to treating HIV infection. Curr Opin HIV AIDS (2011) 0.80
Using the BLT humanized mouse as a stem cell based gene therapy tumor model. J Vis Exp (2012) 0.80
HIV latency is influenced by regions of the viral genome outside of the long terminal repeats and regulatory genes. Virology (2011) 0.78
Gene expression and transcription factor profiling reveal inhibition of transcription factor cAMP-response element-binding protein by gamma-herpesvirus replication and transcription activator. J Biol Chem (2010) 0.77
Rapid size dependent deletion of foreign gene sequences inserted into attenuated HIV-1 upon infection in vivo: implications for vaccine development. Curr HIV Res (2005) 0.76
Animal models of HIV-1 latency and persistence. Curr Opin HIV AIDS (2006) 0.75
Virological evidence supporting the use of raltegravir in HIV post-exposure prophylaxis regimens. Antivir Ther (2012) 0.75
A plea for justice for jailed medical workers. Science (2006) 0.75
Corrigendum: Cocaine exposure impairs multilineage hematopoiesis of human hematopoietic progenitor cells mediated by the sigma-1 receptor. Sci Rep (2015) 0.75